Development and validation of an ELISA-based method for determining neutralizing antibodies to pembrolizumab in human serum based on inhibition of the drug binding to its PD-1 target

Monoclonal antibodies (mAbs) are potentially able to trigger undesired humoral immune responses in the patients and develop ADA (anti-drug antibody) to the protein drugs. Neutralizing anti-drug antibodies are among the main factors affecting safety and effectiveness of the therapy. If it is impossible to apply cell-based tests to determine neutralizing antibodies, competitive ligand binding assay may be used as an alternative. Pembrolizumab (Pembro) is a broad-spectrum antitumor drug, being a humanized IgG4 kappa antibody to the programmed cell death receptor-1 (PD-1) that blocks interaction of this receptor with its ligands PD-L1 and PD-L2. Due to some technical issues, cell culture test is not feasible for Pembro, due to high risk of obtaining unreliable results. The aim of our study was to develop and validate a method for detection of neutralizing antibodies to Pembro in human serum based on inhibition of pembrolizumab binding to its PD-1 target. The experimental drug pembrolizumab RPH-075 (R-Pharm) was used in the study. Anti-Pembrolizumab antibodies KRIBIOLISATM Anti-Pembrolizumab (KEYTRUDA®) ELISA, India) were used as a positive control sample for neutralizing antibodies. Determination of antibodies was carried out by ELISA technique using acid dissociation of the immune complex and the Affinity capture elution (ACE) technique. The ELISA method was validated by the following characteristics: selectivity, sensitivity, specificity, “hook” effect, drug tolerance, precision. Due to the use of sample pretreatment approaches (ACE technique) for analysis of neutralizing antibodies, a sensitivity level of 100 ng/mL was achieved in the presence of pembrolizumab at 40 μg/mL. In this paper, a method was substantiated by calculating the cutoff point, sensitivity, and selectivity based on ROC analysis and floating exclusion limit (PSCP) through the average values of optical density NC and LPC in each individual analytical cycle. The developed method for determining neutralizing antibodies to pembrolizumab may be used to assess the undesirable immunogenicity of pembrolizumab at the stage of clinical trials.

1. Decision of the EEC Council dated 03.11.2016 No. 89 “On approval of the Rules for Conducting Research on Biological Medicinal Products of the Eurasian Economic Union” [Electronic resource]. Available at: https://normativ.kontur.ru/document?moduleId=1&documentId=491692 (date of access: January 15, 2025).

2. Baxi S., Yang A., Gennarelli R.L., Khan N., Wang Z., Boyce L., Deborah K. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ, 2018, Vol. 360, k793. doi: 10.1136/bmj.k793.

3. Butterfield A.M., Chain J.S., Ackermann B.L., Konrad R.J. Comparison of assay formats for drug-tolerant immunogenicity testing. Bioanalysis, 2010, 2 no. 12, pp. 1961-1969.

4. Bourdage J.S., Cook C.A., Farrington D.L., Chain J.S., Konrad R.J. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J. Immunol. Methods, 2007, Vol. 327, no. 1-2, pp. 10-17.

5. Chen Y.Q., Pottanat T.G., Carter Q.L., Troutt J.S., Konrad R.J., Sloan J.H. Affinity capture elution bridging assay: a novel immunoassay format for detection of anti-therapeutic protein antibodies. J. Immunol. Methods, 2016, Vol. 431, pp. 45-51.

6. FDA: Guidance for Industry: Immunogenicity Testing of Therapeutic Protein Products – Developing and Validating Assays for Anti-Drug Antibody Detection. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER) January. 2019. Available at: https://www.fda.gov/media/119788/download.

7. Gupta S., Indelicato S.R., Jethwa V., Kawabata T., Kelley M., Mire-Sluis A.R., Richards S.M., Rup B., Shores E., Swanson S.J., Wakshull E. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods, 2007, Vol. 321, no. 1-2, pp. 10-18.

8. Gunn G.R. 3 rd , Sealey D.C.F., Jamali F., Meibohm B., Ghosh S., Shankar G. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. Clin. Exp. Immunol., 2016, Vol. 184, no. 2, pp. 137-146.

9. Hu J., Wala I., Han H., Nagatani J., Barger T., Civoli F., Kaliyaperumal A., Zhuang Y., Shalini Gupta S. Comparison of cell-based and non-cell based assay platforms for the detection of clinically relevant anti-drug neutralizing antibodies for immunogenicity assessment of therapeutic proteins. J. Immunol. Methods, 2015, Vol. 321, no. 1-2, pp. 1-18.

10. Khoja L., Day D., Wei-Wu Chen T., Siu L.L., Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann. Oncol., 2017, Vol. 28, no. 10, pp. 2377-2385.

11. Knezevic I., Kang H.N., Thorpe R. Immunogenicity assessment of monoclonal antibody products: a simulated case study correlating antibody induction with clinical outcomes. Biologicals, 2015, Vol. 43, no. 5, pp. 5307-5317.

12. Krishna M., Nadler S.G. Immunogenicity to biotherapeutics – the role of anti-drug immune complexes. Front. Immunol., 2016, Vol. 7, 21. doi: 10.3389/fimmu.2016.00021.

13. Mora J., Palmer R., Wagner L., Wu B., Partridge M. 2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard (Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization). Bioanalysis, 2024, Vol. 16, no. 7, pp. 77-119.

14. Nakane P.K., Kawaoi A.J. Peroxidase-labeled antibody. A new method of conjugation. J. Histochem. Cytochem., 1974, Vol. 22, no. 2, pp. 1084-1091.

15. Nath N., Flemming R., Godat B., Urh M. Development of NanoLuc bridging immunoassay for detection of anti-drug antibodies. J. Immunol. Methods, 2017, Vol. 450, pp. 17-26.

16. Niu H., Klem T., Yang J., Qiu Y., Pan L. A biotin-drug extraction and acid dissociation (BEAD) procedure to eliminate matrix and drug interference in a protein complex anti-drug antibody (ADA) isotype specific assay. J. Immunol. Methods, 2017, Vol. 446, pp. 30-36.

17. Richards S. Amaravadi L., Pillutla R., Birnboeck H., Torri A., Kyra J Cowan K.J., Papadimitriou A., Garofolo F., Satterwhite C., Piccoli S., Wu B., Krinos-Fiorotti C., Allinson J., Berisha F., Cocea L., Croft S., Fraser S., Galliccia F., Gorovits B., Gupta S., Gupta V., Haidar S., Hottenstein C., Ishii-Watabe A., Jani D., Kadavil J., Kamerud J., Kramer D., Litwin V., Santos G.M.L., Nelson R., Ni Y., Pedras-Vasconcelos J., Qiu Y., Paul Rhyne P., Safavi A., Saito Y., Savoie N., Kara Scheibner K., Schick E., Siguenza P. Y., Smeraglia J., Staack R.F., Subramanyam M., Sumner G., Thway T., Uhlinger D., Ullmann M., Vitaliti M., Welink J., Whiting C.C., Xue L., Zeng R. White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV):(Part 3–LBA, biomarkers and immunogenicity). Bioanalysis, 2016, Vol. 8, no. 23, pp. 2475-2496.

18. Sasson S.C., Wilkins L.E., Watson R.A., Jolly C., Brain O., Klenerman P., Olsson-Brown A., Fairfax B. Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma. Sci. Rep., 2021, Vol. 11, no. 1, 19253. doi: 10.1038/s41598-021-98700-7.

19. Shankar G., Arkin S., Cocea L., Devanarayan V., Kirshner S., Kromminga A., Quarmby V., Richards S., Schneider C. K., Subramanyam M., Swanson S., Verthelyi D., Yim S. American Association of Pharmaceutical Scientists Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J., 2014, Vol. 16, no. 4, pp. 658-673.

20. Wadhwa M., Knezevic I., Kang H.N., Thorpe R. Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility. Biologicals, 2015, Vol. 43, no. 5, pp. 298-306.

21. Weiner J.A., Natarajan H., Calum J., McIntosh C., Yang E.S., Choe M., Papia C.L., Axelrod K.S., Gabriela Kovacikova G., Pegu A., Ackerman M.E. Selection of positive controls and their impact on anti-drug antibody assay performance. J. Immunol. Methods, 2024, Vol. 528, 113657. doi: 10.1016/j.jim.2024.113657.

22. Wu B., Chung S., Jiang X.-R., McNally J., Pedras-Vasconcelos J., Pillutla R., White J.T., Xu Y., Gupta S. Strategies to determine assay. format for the assessment of neutralizing antibody responses to biotherapeutics. AAPS J., 2016, Vol. 18, no. 6, pp. 1335-1350.

23. Wu B.W., Gunn G.R. III, Shankar G. Competitive Ligand-Binding Assays for the Detection of Neutralizing Antibodies. Detection and quantification of antibodies to biopharmaceuticals: practical and applied considerations. In: Tovey M.G. (ed.). Detection and Quantification of Antibodies to Biopharmaceuticals. Wiley, 2011, pp. 175-192.

24. Wu B., Schnarr M., Devlin J.L., Brown S., Yang T.-Y. Approaches to improve drug tolerance and target tolerance in the assessment of neutralizing anti-drug antibodies. Bioanalysis, 2019, Vol. 11, no. 22, pp. 2061-2074.

25. Xiang Y., Parng C., Olson K., Seletskaia E., Gorovits B., Jani D., Caiazzo T., Joyce A., Donley J. Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody. AAPS J., 2019, Vol. 21 no. 3, 46. doi: 10.1208/s12248-019-0320-3.

26. Zoghbi J., Xu Y., Grabert R., Theobald V., Richards S. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays. J. Immunol. Methods, 2015, Vol. 426, pp. 62-69.